Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Adenosine is an endogenous purine nucleoside and a fundamental building block of RNA. Pharmacologically, it acts as an agonist at four G-protein-coupled adenosine receptors (A1, A2A, A2B, and A3), modulating numerous physiological processes including cardiac conduction, vasodilation, neurotransmission, and immune response. Clinically, intravenous adenosine is used for the acute conversion of paroxysmal supraventricular tachycardia (PSVT) to normal sinus rhythm and as a diagnostic agent in myocardial perfusion imaging for patients unable to exercise adequately. Its antiarrhythmic effect is mediated by slowing conduction through the atrioventricular node via hyperpolarization of cardiac cells. Adenosine has a very short half-life (<10 seconds) due to rapid cellular uptake and metabolism[1][7][8]. It also plays roles in neuroprotection during hypoxia or ischemia and has been investigated for its effects on sleep regulation, pain modulation, inflammation control, and potential involvement in neurodegenerative diseases[2][5][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on adenosine.